MENLO PARK, Calif.--(BUSINESS WIRE)--SRI International, an independent nonprofit research and development organization, today announced that it has been awarded a $56.9 million contract with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to provide preclinical services for the development of drugs and antibodies for anti-infective therapeutics.
